Korro Bio (KRRO) - Forward P/S Multiple
The development of KRRO-110 and the alliance with Novo Nordisk are driving value growth for Korro Bio, Inc. (KRRO). Its status as a scientific visionary in the therapy of genetic pathologies supports the company's forward P/S ratio, where 152.80 determines the current magnitude of the metric. This chart illustrates market expectations, while a robust patent shield and FDA oversight create an insurmountable barrier for new entrants.
Analytical breakdowns for Korro Bio, Inc.
- stock price and consensus target price:
- market capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Equity Ratio Korro Bio, Inc.|KRRO - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Korro Bio|KRRO - Company Aggregate Debts|Debt to Book Capitalization Ratio Korro Bio|KRRO - Company Long-Term Loans and Borrowings|Company Short-Term Debt Korro Bio|Quick Liquidity korrobio.com
- business earnings and investment ratios data:
KRRO - Company Net Income|Projected Future Earnings Korro Bio, Inc.|KRRO - Price to Earnings Multiple|Future Price to Earnings Korro Bio|KRRO - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Korro Bio|KRRO - Operating profit EBITDA|Earnings per share for the last twelve months Korro Bio|KRRO - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months korrobio.com|KRRO - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Korro Bio, Inc.
- sales and revenue indicators:
Fundamental company analysis:KRRO (Korro Bio, Inc)
The forward P/S ratio measures the relationship between the market value of Korro Bio, Inc. (KRRO) and its projected revenue, allowing investors to filter out market noise and identify the actual business revaluation by institutional players. By analyzing the forward P/S ratio, one can assess the monetization potential of RNA editing technologies within the genetic therapy segment, which determines the company's fundamental stability during its expansion into B2B and B2C markets.
Key competitors
Tempus AI, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales QGEN|Ionis Pharma - Forward P/S Multiple|Market Cap to Expected Sales Ratio Repligen Inc. RGEN|Avidity Biosciences (RNA) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue CRSP|WGS (GeneDx) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Ultragenyx Pharmaceutical Inc. (RARE)|Forward Price-to-Revenue Multiple BEAM (Beam Therapeutics Corp)|Market Cap to Expected Sales Ratio Sarepta Corp|Price-to-Projected Revenue Ratio Twist Bioscience TWST|Forward P/S Multiple 10xgenomics.com TXG|NTLA - Price-to-Projected Revenue Ratio|Forward Price to Sales STOK (Stoke Therapeutics Inc)|BioLife Corp (BLFS) - Price-to-Projected Revenue Ratio|Wave Pharma - Forward Price to Sales|Price-to-Projected Revenue Ratio Maze Therapeutics Inc|Market Cap to Future Revenue Ratio sionnatx.com SION|Forward P/S Multiple PRME|Taysha Gene Therapies Inc - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio uniQure Corp QURE|MGTX: Market Cap to Projected Revenue|REGENXBIO Inc. - Forward P/S Multiple|SLDB - Forward P/S Multiple|Ocugen (OCGN) - Price-to-Projected Revenue Ratio|Pacific Biosciences of California, Inc. (PACB) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Benitec|Market Cap to Future Revenue Ratio Design Corp DSGN|Price-to-Projected Revenue Ratio Rocket Pharmaceuticals (RCKT)|FDMT (4dmoleculartherapeutics.com) - Forward Price to Sales|Price-to-Projected Revenue Ratio Lexeo Therapeutics, Inc. LXEO|Forward Price to Sales EDIT|SLN - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio ProQR Therapeutics N.V.|CDXS (codexis.com) - Forward Price-to-Revenue Multiple|sangamo.com - Forward Price to Sales|NAUT (Nautilus Biotechnology, Inc.) - Forward P/S Multiple|Price-to-Projected Revenue Ratio MGX|Forward P/S Multiple DTIL|Market Cap to Expected Sales Ratio generationbio.com|Price-to-Projected Revenue Ratio Boundless Bio, Inc. BOLD|Exicure Inc. (XCUR) - Market Cap to Future Revenue Ratio|IMNN: Forward Price-to-Revenue Multiple|Forward Price to Sales PHIO (Phio Pharmaceuticals)|MBIO: Forward P/S Multiple|RNAZ - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Bionano Genomics Inc.|Market Cap to Projected Revenue APDN (adnas.com)|Forward P/S Multiple BLUE|Forward Price-to-Revenue Multiple immunoprecise.com IPA|Omega - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Singular Genomics Corp (OMIC)|RGLS - Price-to-Projected Revenue Ratio|SYRS - Forward P/S Multiple|Telesis Bio (TBIO) - Price-to-Projected Revenue Ratio|TRACON Pharmaceuticals Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Unity Bio
